Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Glas · SciRah

Researcher profile · Semantic Scholar

M. Glas

Share profile

M. Glas — researcher profile on SciRah

h-index: 39
Works: 252
Citations: 5,092

Most-cited papers

Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
C. Hertler, J. Felsberg, D. Gramatzki, É. Le Rhun +46 more
2023European Journal of Cancer77 citations Open access
Semantic Scholar
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
F. Giordano, J. P. Layer, S. Leonardelli, L. Friker +18 more
2024Nature Communications68 citations Open access
Semantic Scholar
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine
Pauline Latzer, H. Zelba, Florian Battke, Annekathrin Reinhardt +46 more
2024Nature Communications68 citations Open access
Semantic Scholar
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
N. Hirmas, R. Hamacher, M. Sraieb, M. Ingenwerth +24 more
2022Journal of Nuclear Medicine67 citations Open access
Semantic Scholar
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.
M. Ratliff, K. Karimian-Jazi, D. Hoffmann, L. Rauschenbach +17 more
2023Neuro-Oncology53 citations Open access
Semantic Scholar
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
I-Na Lu, C. Dobersalske, L. Rauschenbach, Sarah Teuber-Hanselmann +11 more
2021Nature Communications47 citations Open access
Semantic Scholar
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
L. Bunse, Anne-Kathleen Rupp, I. Poschke, T. Bunse +15 more
2022Neurological Research and Practice43 citations Open access
Semantic Scholar
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
M. Glas, M. Ballo, Z. Bomzon, N. Urman +13 more
2021International Journal of Radiation Oncology, Biology, Physics43 citations Open access
Semantic Scholar
Effectiveness and tolerability of lacosamide as add‐on therapy in patients with brain tumor–related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES)
R. Rudà, C. Houillier, M. Maschio, J. Reijneveld +7 more
2020Epilepsia38 citations Open access
Semantic Scholar
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
T. Zeyen, A. Potthoff, R. Németh, D. Heiland +28 more
2022Trials32 citations Open access
Semantic Scholar
Fully Automated MR Based Virtual Biopsy of Cerebral Gliomas
J. Haubold, R. Hosch, V. Parmar, M. Glas +9 more
2021Cancers31 citations Open access
Semantic Scholar
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
A. Scheffler, Hannah Schenk, S. Wurthmann, Michael Nsaka +3 more
2021The Journal of Headache and Pain30 citations Open access
Semantic Scholar
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Eleftheria Chorti, S. Kebir, Misbah S. Ahmed, K. Keyvani +14 more
2021European Journal of Cancer29 citations
Semantic Scholar
Theranostics in Neurooncology: Heading Toward New Horizons
N. Tolboom, A. Verger, N. Albert, F. Fraioli +13 more
2023Journal of Nuclear Medicine21 citations Open access
Semantic Scholar
“A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression”
T. Tzaridis, J. Weller, Daniel Bachurski, Farhad Shakeri +17 more
2022International Journal of Cancer20 citations Open access
Semantic Scholar
Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
Michael Nsaka, A. Scheffler, S. Wurthmann, Hannah Schenk +3 more
2022Brain and Behavior18 citations Open access
Semantic Scholar
Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose–response relationships
N. Mikic, N. Gentilal, Fang Cao, E. Lok +6 more
2024Neuro-Oncology Advances15 citations Open access
Semantic Scholar
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
L. Lazaridis, E. Bumes, Dorothee Cäcilia Spille, T. Schulz +23 more
2022Neuro-Oncology Advances15 citations Open access
Semantic Scholar
Protocadherin Gamma C3 (PCDHGC3) Is Strongly Expressed in Glioblastoma and Its High Expression Is Associated with Longer Progression-Free Survival of Patients
J. Feldheim, David Wend, Mara J. Lauer, C. Monoranu +7 more
2022International Journal of Molecular Sciences14 citations Open access
Semantic Scholar
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial
T. Tzaridis, N. Schäfer, J. Weller, J. Steinbach +20 more
2020International Journal of Cancer14 citations Open access
Semantic Scholar
To resect or not to resect? Risks and benefits of surgery in older patients with glioblastoma.
Y. Ahmadipour, L. Rauschenbach, O. Gembruch, Marvin Darkwah Oppong +6 more
2020Journal of Geriatric Oncology14 citations
Semantic Scholar
Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
L. Lazaridis, T. Schmidt, C. Oster, T. Blau +13 more
2022Journal of Cancer Research and Clinical Oncology13 citations Open access
Semantic Scholar
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic
Na Tosha N. Gatson, J. Barnholtz-Sloan, J. Drappatz, R. Henriksson +7 more
2021Frontiers in Oncology13 citations Open access
Semantic Scholar
Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography
S. Kebir, L. Rauschenbach, Manuel Weber, L. Lazaridis +18 more
2021Journal of Neuro-Oncology13 citations
Semantic Scholar
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
Hannah Schenk, D. Holle, Michael Nsaka, C. Kleinschnitz +2 more
2022The Journal of Headache and Pain12 citations Open access
Semantic Scholar
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells
J. Feldheim, A. Kessler, Julia J. Feldheim, E. Schulz +9 more
2022International Journal of Molecular Sciences12 citations Open access
Semantic Scholar
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
N. Grassl, K. Sahm, Heike Süße, I. Poschke +21 more
2023Neurological Research and Practice10 citations Open access
Semantic Scholar
Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis
N. Guberina, Florian Padeberg, C. Poettgen, M. Guberina +13 more
2023Cancers9 citations Open access
Semantic Scholar
Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma.
Wen-Yin Shi, D. Roberge, L. Kleinberg, S. Jeyapalan +8 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Evaluation of [68Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space
A. Milosevic, H. Styczen, J. Grueneisen, Yan Li +15 more
2023Journal of Nuclear Medicine8 citations Open access
Semantic Scholar
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial
F. Giordano, J. P. Layer, R. Turiello, L. Friker +27 more
2026Nature Communications7 citations Open access
Semantic Scholar
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
J. Weller, N. Schäfer, C. Schaub, T. Tzaridis +24 more
2023Journal of Neuro-Oncology6 citations Open access
Semantic Scholar
Challenging implications of CLIPPERS syndrome with atypical presentation: report of two cases.
L. Rauschenbach, S. Kebir, A. Radbruch, M. D. Oppong +7 more
2020World Neurosurgery6 citations
Semantic Scholar
Tumor treating fields (TTFields) therapy in patients with glioblastoma: Long-term survival results from TTFields in Germany in routine clinical care (TIGER) study.
O. Bähr, G. Tabatabai, R. Fietkau, R. Goldbrunner +1 more
2024Journal of Clinical Oncology5 citations
Semantic Scholar
Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.
F. Giordano, J. Layer, S. Leonardelli, L. Friker +16 more
2023Journal of Clinical Oncology5 citations
Semantic Scholar
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
S. Kebir, V. Ullrich, P. Berger, C. Dobersalske +30 more
2022Clinical Cancer Research5 citations Open access
Semantic Scholar
Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma
T. Schmidt, S. Kebir, E. Livingstone, A. Junker +13 more
2021Frontiers in Oncology5 citations Open access
Semantic Scholar
Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies
J. Feldheim, C. Deuschl, M. Glas, C. Kleinschnitz +1 more
2021Neurological Research and Practice5 citations Open access
Semantic Scholar
Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF‐phase I/II trial
Y. Nour, C. Pöttgen, S. Kebir, L. Lazaridis +14 more
2021Journal of Applied Clinical Medical Physics5 citations Open access
Semantic Scholar
Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.
G. Tabatabai, L. von Baumgarten, M. J. van den Bent, Michael C. Burger +16 more
2024Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Benchmarking palliative care practices in neurooncology: a german perspective
A. L. Lawson McLean, A. Lawson McLean, T. Ernst, M. Forster +43 more
2024Journal of Neuro-Oncology4 citations Open access
Semantic Scholar
Telemedicine in Neuro-Oncology—An Evaluation of Remote Consultations during the COVID-19 Pandemic
J. Feldheim, T. Schmidt, C. Oster, Julia J. Feldheim +10 more
2023Cancers4 citations Open access
Semantic Scholar
Brain tumor patients and COVID-19 vaccines: results of an international survey
M. Voisin, K. Oliver, Stuart Farrimond, Tess Chee +15 more
2022Neuro-Oncology Advances4 citations Open access
Semantic Scholar
CTIM-08. FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASE
G. Tabatabai, P. Frères, M. Glas, P. Hau +16 more
2024Neuro-Oncology3 citations Open access
Semantic Scholar
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
T. Zeyen, Daniel Paech, J. Weller, N. Schäfer +21 more
2023Journal of Neuro-Oncology3 citations Open access
Semantic Scholar
BRMS1 in Gliomas—An Expression Analysis
J. Feldheim, A. Kessler, Julia J. Feldheim, D. Schmitt +7 more
2023Cancers3 citations Open access
Semantic Scholar
QOLP-31. QUALITY OF LIFE OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA DURING TTFIELDS THERAPY IN ROUTINE CLINICAL CARE: FIRST RESULTS OF THE TIGER STUDY
O. Bähr, G. Tabatabai, R. Fietkau, R. Goldbrunner +1 more
2021Neuro-Oncology3 citations Open access
Semantic Scholar
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
T. Zeyen, L. Böhm, Daniel Paech, N. Schäfer +25 more
2024Neuro-Oncology2 citations Open access
Semantic Scholar
Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011–2022.
M. Mrugala, Wen-Yin Shi, F. Iwamoto, R. Lukas +3 more
2023Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma
Wen-Yin Shi, L. Kleinberg, S. Jeyapalan, S. Goldlust +8 more
2023Cancer Research2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Kebir×15
Invite
S. Kebir — researcher profile on SciRah
B. Scheffler×12
Invite
B. Scheffler — researcher profile on SciRah
U. Sure×11
Invite
U. Sure — researcher profile on SciRah
C. Kleinschnitz×11
Invite
C. Kleinschnitz — researcher profile on SciRah

×10

Invite

L. Lazaridis — researcher profile on SciRah

Invite

M. Stuschke — researcher profile on SciRah

R. Goldbrunner×9

Invite

R. Goldbrunner — researcher profile on SciRah

U. Herrlinger×8

Invite

U. Herrlinger — researcher profile on SciRah

Invite

C. Schaub — researcher profile on SciRah

Invite

C. Oster — researcher profile on SciRah

U. Herrlinger×8

Invite

U. Herrlinger — researcher profile on SciRah

G. Tabatabai×8

Invite

G. Tabatabai — researcher profile on SciRah